285 related articles for article (PubMed ID: 22109574)
1. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
3. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
4. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
5. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
7. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
8. [JAK2 mutation and thrombosis - recommendations for screening].
Held M
Dtsch Med Wochenschr; 2012 Feb; 137(5):227. PubMed ID: 22278696
[No Abstract] [Full Text] [Related]
9. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
10. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Hexner EO
Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
15. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
16. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
18. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
19. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
Plo I; Vainchenker W
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]